TWI889871B - 抗α-４-β-７抗體 - Google Patents

抗α-４-β-７抗體

Info

Publication number
TWI889871B
TWI889871B TW110126301A TW110126301A TWI889871B TW I889871 B TWI889871 B TW I889871B TW 110126301 A TW110126301 A TW 110126301A TW 110126301 A TW110126301 A TW 110126301A TW I889871 B TWI889871 B TW I889871B
Authority
TW
Taiwan
Prior art keywords
seq
human
antibody
cells
binding
Prior art date
Application number
TW110126301A
Other languages
English (en)
Chinese (zh)
Other versions
TW202216781A (zh
Inventor
靜 閔
泰瑞莎 洛克 誠 王
洛瑞歐 班那吐爾
傑可奎琳 比克斯貝
塔狄安娜 德克蒂爾
峰 董
艾瑟爾 二世 赫南德茲
普瑞西 克里斯南
良軍 陸
費德里歌 曼沙
瑞尼 米勒
高譚 薩胡
Original Assignee
美商艾伯維有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商艾伯維有限公司 filed Critical 美商艾伯維有限公司
Publication of TW202216781A publication Critical patent/TW202216781A/zh
Application granted granted Critical
Publication of TWI889871B publication Critical patent/TWI889871B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
TW110126301A 2020-07-16 2021-07-16 抗α-４-β-７抗體 TWI889871B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063052933P 2020-07-16 2020-07-16
US63/052,933 2020-07-16

Publications (2)

Publication Number Publication Date
TW202216781A TW202216781A (zh) 2022-05-01
TWI889871B true TWI889871B (zh) 2025-07-11

Family

ID=77338969

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110126301A TWI889871B (zh) 2020-07-16 2021-07-16 抗α-４-β-７抗體

Country Status (15)

Country Link
US (2) US11639390B2 (enExample)
EP (1) EP4182349A1 (enExample)
JP (2) JP7408008B2 (enExample)
KR (1) KR20230038728A (enExample)
CN (1) CN115867352A (enExample)
AR (1) AR122983A1 (enExample)
AU (1) AU2021307468A1 (enExample)
CA (1) CA3188739A1 (enExample)
CO (1) CO2023001066A2 (enExample)
IL (1) IL299767A (enExample)
MX (1) MX2023000732A (enExample)
TW (1) TWI889871B (enExample)
UY (1) UY39327A (enExample)
WO (1) WO2022016198A1 (enExample)
ZA (1) ZA202300222B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202504919A (zh) 2023-05-30 2025-02-01 美商派拉岡醫療公司 α4β7整合素抗體組合物及使用方法
WO2025038861A1 (en) * 2023-08-15 2025-02-20 Abbvie Inc. Methods of treating human immunodeficiency virus (hiv) disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018104893A1 (en) * 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1135498B1 (en) 1998-11-18 2008-01-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
AP2015008338A0 (en) * 2012-09-26 2015-04-30 Kflp Biotech Llc Compounds for the treatment and prevention of retroviral infections

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018104893A1 (en) * 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life

Also Published As

Publication number Publication date
MX2023000732A (es) 2023-02-13
CA3188739A1 (en) 2022-01-20
JP7765447B2 (ja) 2025-11-06
UY39327A (es) 2022-02-25
CN115867352A (zh) 2023-03-28
BR112023000718A2 (pt) 2023-02-07
KR20230038728A (ko) 2023-03-21
EP4182349A1 (en) 2023-05-24
ZA202300222B (en) 2023-09-27
CO2023001066A2 (es) 2023-02-06
JP7408008B2 (ja) 2024-01-04
US20220017624A1 (en) 2022-01-20
US11639390B2 (en) 2023-05-02
TW202216781A (zh) 2022-05-01
AU2021307468A1 (en) 2023-02-02
JP2024037932A (ja) 2024-03-19
AR122983A1 (es) 2022-10-19
IL299767A (en) 2023-03-01
WO2022016198A1 (en) 2022-01-20
US20260062488A1 (en) 2026-03-05
JP2023535556A (ja) 2023-08-18

Similar Documents

Publication Publication Date Title
US20230406946A1 (en) Antibodies and methods of use thereof
US20230167186A1 (en) Methods of administering anti-ox40 antibodies
CN111138542B (zh) 双特异性抗体及其用途
WO2022170126A2 (en) Compounds specific to coronavirus s protein and uses thereof
JP2019522961A (ja) Ｔｌ１ａ抗体およびその使用
US20260062488A1 (en) Anti-alpha-4-beta-7 antibodies
BR122024013054A2 (pt) Anticorpo monoclonal humano anti-alfa-4--beta-7
BR112023000718B1 (pt) Anticorpo monoclonal anti-alfa-4-beta-7 humano
CN116685603A (zh) B和t淋巴细胞衰减因子（btla）调节剂及其使用方法
HK40107549A (zh) 抗c-c基序趋化因子受体8(ccr8)抗体以及使用方法
EA048894B1 (ru) Антитела к l1cam и их применение